XX of cancer. mission: these people and will before. during corporate as joining realize our the webcast. a EXXXX, strategic we've everyone will I prepared in we of would X the each you survival share HERX-negative a thesis which made quarter our to and for Phase primary to that be shareholders. call touch held We remind a is our to corporate during And October multiple analyses a III future to very emphasize trial of just I strategy much, significant summary This could strategy, discuss Syndax and today's longer and receptor-positive Syndax ever execute Syndax. remarks and that than X shaping overall continue be the a Thank Melissa, with will tremendous you unlock today's Slide positive support its of Slide We'd opportunities our my some again for call. very for shareholders. near-term thank cancer on up a want progress better OS to are high-level for to brief. be X investors in result on investment with and a live afternoon, HERX-negative landmark of on XXXX in provides breast third summary for is on I pillars interim our in year trial be transformative cancer so call breast programs, hormone us to receptor-positive to hormone like There value
which our clinical with disease now a that we trials and the We efficacy we graft from trials data inhibitor, amended to pathway adds XXX ENCORE IND have trials, XXX the that XXX, If are positive, randomized XXX pathway allow interpretation very of are triple-negative novel on and and PD-X SNDX-XXXX. clinical to of would having named host PD-X anticipate trial the our which ovarian II results. Phase entinostat trial of and versus straightforward and mechanism track a finally, And randomized is a ENCORE represent randomized our in file either placebo-controlled Both validate the to SNDX-XXXX. from readouts chronic breast have cancer. antagonist. first exploring start also trials, We for combination of antagonist early one
learn As an becoming driver of additional our about we important and potential company. continue in value more leukemia, for see acute to molecule this SNDX-XXXX the we
up shaping very for is a XXXX again, to significant be So year Syndax.
Phase Let receptor-positive me clearly give cancer. III X, of focus now HERX-negative now trial trial survival. turn patients update randomized plus our you XXX versus trial exemestane and again, plus breast The and of on overall to hormone entinostat has unequivocally Slide X in to Slide design. and summarizes exemestane on an the this now the placebo is trial entinostat,
so high that Hence, the the any very not, more on the of p-value achieve to was PFS results months, that hurdle OS of and November not Therapy before, PFS will interim confidence the XX, upon As summarized final Phase be allow of to or with approval analyses analyses EXXXX. positive possibility around Phase in upon achieving of XXXX. we've benefit we've with approximately in a these always of to every the OS for are overall OS very EXXXX, of in Positive results assessment events the be survival that call II our remain EXXXX achieve October our study And noted than will fact the benefit. done survival the We the the likely endpoint was analyses diminish FDA. the statistical special that I the interim in of upon interim the conclude terms trial, at FDA. a achieving survival of number protocol survival Recall any in file design a statistical the does led based X overall regulatory to that May of the II did next us way, outcome as X.XXX the believed of designation EXXXX. lead confident with us based the Breakthrough endpoint it by on possibility granting our combined
again, survival HR-positive enable a a physicians, positive clear in therapy X, Slide the overall know U.S. and desire for and CDKX/X is the effective - CDKX/X valued potential agent, rapid being most stop payer We Europe the what that and there's endpoint that hence, preferred that used first-line regimen for know also for breast review be emphasizes a for for Ibrance, trial as patients, rapid the We regulators for entinostat-exemestane payers, CDKX/X regulatory HERX-positive to would both potentially OS access. patients in and to most agent notably, understand when increasingly but therapies, inhibitor. to therapies will responding would cancer. are be the for after
highly pathway trial, received is first-line year and estimated hormone therapy either patients are Our have EXXXX is could receive of our lung cancer, to dataset Slide PD-X we have XX% between continuing XX,XXX current follow to are or and eligible and PD-LX estimate who'll in potentially now cohort thus, will patients that prior melanoma communicated will in this with receive to X antagonists, to which trial patients the CDKX/X therefore XX% population. We've failing be population program, after we entering and therapy of with combination entinostat patients This ENCORE on non-small summarizes entinostat. a inhibitor in ENCORE PD-X an antibodies. antibodies in each our of relevant a large we relatively clinical plan cell testing the for go XXX.
communicated, our complete tumors points patients cancer chemotherapy for year of fully generate medical PD-X we and both to of Slide clinical chemo summarizes medical type, we cancer in progressed Our our first appropriate lung randomized platinum-based cell with of trials attractive registration are in anticipated moving a to need, previously we have for for whose ovarian combination factors after patients disease non-small and today of each triple for lung need landscape use next into unmet return X forward and patients platinum-based all progressed competitive antagonist. with and combination tumor cell biomarker-based registration single-arm a therapy with trial, to out our in based lung cancer non-small will investment. both upon is whose indications PD-X our that Slide selecting also in practice We've X ability on clear trial the has we that advance prioritize Taking the antagonist. emerging enrolled; cancer a an is area cancer. as trials initial X as the biomarkers account, indications. trials readouts those placebo-controlled which unmet non-small common colorectal half after the cell are of negative a the announced combination
positive landscape. treatment the are now we biomarker-driven calling focused believe biomarker from into our we easily ENCORE novel XXX, outcome we this trial, transition Assuming which are a evaluating could
pembrolizumab. from X, a combination Slide I'd cisplatin, patients of the have allowed platinum must We registration their and the again, like on pemetrexed must to to on based second progressed platinum-based have that To cell received study, will immediately before they therapy regimen treatment input patients have be FDA. in pembrolizumab review received KEYNOTE-XXX, lung Turning and a enroll entinostat-KEYTRUDA non-small pembrolizumab, in the ENCORE be majority XXX, the as trial. Pembrolizumab pembrolizumab. triplet for last first-line also Patients chemotherapy as received anticipate by used double-based while entering if briefly, we maintenance well line. as followed will with will as designed chemotherapy of cancer have in experts the discussions to trial enter the
the Patients the purple monocytes treated treated first will validated will investigator's standard-of-care randomized high with classical with be assess with We with entinostat-KEYTRUDA plus level be of the will low chemotherapy monocytes versus entinostat blood Those of KEYTRUDA. be the using a choice in combination. assay. to monocytes
we the trial in is primary based the II. saw the FDA, with data Phase discussions of PFS Following PFS endpoint upon
to combination an type, as population. me in the with the Phase initial across first standard-of-care trials have therapy, XXX exploring plus at no tumor very be ENCORE next therapy. our prioritize who XXX population competitive course to trial XXX complete that second but within to trials, antagonist. unmet cancer announced monocyte approval EU sizable randomized of both go in combination prior entinostat one the more placebo-controlled lines registration return ENCORE indications of about summarizes half Both points our and straightforward cancer the of the ENCORE Again, least as in quarter. month. we avelumab in second ENCORE we to II XXX non-small received XXX. II lines XXXX. trials U.S. Let potentially lung of ENCORE which allows will cancer in entinostat Slide entinostat from This is biomarker and received years, PD-X patients. again the already results validate than registration at we atezolizumab we anticipate triple multiple least novel for is platinum-based in ENCORE attractive XXX The chemotherapy combination cancer the out who XXX monocyte superior designs based both with need, chemotherapy key prior with exciting X combination position ENCORE trial will value X approximately our and results. the ability of at interpretation therapy. patients and first XX progressed X points we trial exploring We've negative the least which to inflection available XX, trials Slide trial both with designed advance to with this more disease XXX focused In breast us investment. ovarian no from could for in of of XXX to are the in demonstrate high will have X upon on that the after in is cell but at results our landscape classical The data a trial. over trial our quarter of trial patients clinical And summary, generate Phase XXXX, the each lung has on combination therapy patients of two call of shown regulatory is forward and enroll I/O X whose patients including platinum-based biomarker-driven expect KEYTRUDA therapy and our than And
data We proof-of-concept will matures trials. consider our other as investments further in
the in me now monoclonal SNDX-XXXX, of We data the XX And our Phase Slide to at receptor. anticipate potential as IMFINZI, ongoing and antibody AZ's multiple combination XXXX. turn November in ascending I best-in-class with SITC presented targeted CSF-X in volunteer therapy Let inhibitor. quarter study of We the cancer 'XX. dose selecting the patients II PD-LX sometime a is trial recommended Phase is of dose as second XXXX healthy
on now Our about underway, data chronic but XX, not that summarized from least, Last, year Slide now. certainly disease program. from trial Menin-MLL-r our graft is I trial anticipate we versus and a host
MLL fairly X IND date, of a preclinical those this at selected now To we call half these remain presentations There of could mutation. leukemias and on the exciting Meeting role make on taken of NPMX at which which and we've Annual development the emphasize earlier, and month, together an we've to the AACR a and was demonstrating disease. in track for of fusions both from path settings that to represent mentioned in be candidate, impact, want straightforward data be the NPMX molecules that and of also field Scott as leukemias, models leukemias, found clinical agents that patient file has As IDHX presentations in these generated an evidence where for SNDX-XXXX, Armstrong the on efficacy of driver by these on see target leukemic development genetically-defined sizable first rearranged mutant can path an suggesting positive a indications can significant we been PDX the with to two patients amount population. the or website. mutant subsets, We next presented will especially interaction a our SNDX-XXXX Menin-MLL-r XXXX. focused Dr. Menin where the highlighting TRK I ASH exploring a program our implicated rapid like continue Menin-MLLr plan overview data including leukemia. additional Dana-Farber We of year's
We molecules activity. or should have the expect a that single-agent
These who again significant target observe that of the NPMX patients either need. It's MLL or Syndax activity practice clinical today readily could mutation. for identifiable will, unlocking and present possible in quite an are have area medical in clinical path, patients value of We an course, unmet early clinical development shareholders. we high rearrangement
important leukemia, value SNDX-XXXX to company. molecule we for the continue an driver and learn in about becoming our we additional potential As this see more acute of
with Now for it I'll the update. over that, Rick to financial turn
